Jaguar Health secures $40M equity line and closes $2M preferred stock financing

The company raised $2 million through a private placement of 240 shares of Series P Non-Convertible Preferred Stock, which closed on June 9, 2026. The proceeds will be used for general corporate purposes subject to restrictions in the purchase agreements. The company will also issue pre-funded warrants worth $72,000 to the investors as consideration for entering the agreements.

The company obtained stockholder approval at its reconvened Annual Meeting on June 8, 2026, which removes the 19.99% cap on common stock issuance related to preferred stock redemption and exchange. This approval was required under the Preferred Stock Purchase Agreements and allows the company to issue additional shares beyond the initial threshold.

Prior to stockholder approval, the company was restricted from issuing common stock upon preferred share redemption or exchange if total issuance would exceed 19.99% of outstanding shares. With approval now obtained, this restriction is lifted, potentially allowing significant dilution of existing common stockholders as preferred shares convert to common stock.

The company disclosed that securities under the Preferred Stock Purchase Agreements and ELOC Agreement were sold without SEC registration, using private placement exemptions to accredited investors. This is a standard disclosure for private financing transactions but confirms the company raised capital through unregistered offerings.

The company filed a Certificate of Designation with Delaware on June 8, 2026, authorizing up to 300 shares of Series P Preferred Stock with a stated value of $10,000 per share. This represents a new class of preferred stock issued in connection with the Preferred Stock Financing disclosed elsewhere in the 8-K.

Each share of Series P Preferred Stock accrues dividends at 8% annually on its $10,000 stated value, payable quarterly in either cash or common stock at the company's election. This creates a recurring obligation that could dilute common shareholders if paid in stock.

The company must redeem at least 10% of Series P Preferred Stock whenever it receives proceeds from the ELOC Agreement, payable in cash or common stock. This ties preferred stock redemption directly to equity line draws, creating potential dilution when the company accesses that capital facility.

Multiple triggering events allow preferred holders to force redemption, including registration statement failures, trading suspensions lasting five days, failure to pay dividends for two trading days, or shares remaining outstanding after three years. These provisions give preferred holders significant control and could force dilutive common stock issuances.

Series P Preferred Stock ranks senior to common stock in liquidation, with each share entitled to its stated value plus accrued dividends before common shareholders receive anything. Deemed liquidation events include mergers where shareholders lose majority control or asset sales, protecting preferred holders in change-of-control scenarios.

The company entered into an equity line of credit (ELOC) agreement with an institutional investor on June 9, 2026. This financing arrangement typically allows the company to draw funds by selling shares to the investor over time, providing flexible capital access. The specific terms, size, and conditions are contained in the agreement exhibit.

The company created a new class of Series P Non-Convertible Preferred Stock by filing a certificate of designation. This preferred stock does not convert to common shares and likely carries specific dividend, liquidation, or voting rights. The creation of non-convertible preferred suggests a financing structure that avoids immediate common share dilution.

The company issued pre-funded warrants at commencement of the transaction. Pre-funded warrants are typically sold at a price near the stock's current market value minus a nominal exercise price, functioning as near-equity instruments that allow investors to acquire shares with minimal additional payment. This structure is common in registered direct offerings.

The company executed purchase agreements for the Series P preferred stock with multiple investors on June 9, 2026. These agreements govern the sale terms, representations, and conditions for the preferred stock issuance. The use of multiple registration rights agreements suggests participation by several institutional or accredited investors.

The company granted registration rights to investors in both the ELOC and preferred stock transactions. Registration rights obligate the company to register the underlying securities with the SEC, allowing investors to resell shares publicly. This is standard in private placements and indicates the investors expect liquidity through public market sales.